71 related articles for article (PubMed ID: 2684003)
21. Evaluation of mithramycin in the treatment of anaplastic gliomas.
Walker MD; Alexander E; Hunt WE; Leventhal CM; Mahaley MS; Mealey J; Norrell HA; Owens G; Ransohoff J; Wilson CB; Gehan EA
J Neurosurg; 1976 Jun; 44(6):655-67. PubMed ID: 178838
[TBL] [Abstract][Full Text] [Related]
22. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.
Heimberger AB; Kong LY; Abou-Ghazal M; Reina-Ortiz C; Yang DS; Wei J; Qiao W; Schmittling RJ; Archer GE; Sampson JH; Hiraoka N; Priebe W; Fuller GN; Sawaya R
Clin Neurosurg; 2009; 56():98-106. PubMed ID: 20214040
[No Abstract] [Full Text] [Related]
23. Early vs. delayed radiotherapy in a small cohort of patients with supratentorial low grade glioma.
Knisely JP; Haffty BG; Christopher SR
J Neurooncol; 1997 Aug; 34(1):23-9. PubMed ID: 9210050
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors for high-grade malignant glioma: development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party.
J Neurooncol; 1990 Aug; 9(1):47-55. PubMed ID: 2213115
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy of the brain in elderly patients. Contra:
Brandes AA; Rigon A; Monfardini S
Eur J Cancer; 2000 Mar; 36(4):447-51; discussion 451-2. PubMed ID: 10717519
[No Abstract] [Full Text] [Related]
26. Brain-tumor cell kinetics correlated with survival.
Bookwalter JW; Selker RG; Schiffer L; Randall M; Iannuzzi D; Kristofik M
J Neurosurg; 1986 Dec; 65(6):795-8. PubMed ID: 3772478
[TBL] [Abstract][Full Text] [Related]
27. Weighing the benefits and risks of radiation therapy for low-grade glioma.
Peterson K; DeAngelis LM
Neurology; 2001 May; 56(10):1255-6. PubMed ID: 11376168
[No Abstract] [Full Text] [Related]
28. Survival in malignant gliomas.
Alvord EC
J Neurosurg; 1994 Feb; 80(2):350-1. PubMed ID: 8283279
[No Abstract] [Full Text] [Related]
29. From the files of the KMA Maternal Mortality Study Committee.
Greene JW
J Ky Med Assoc; 1978 Aug; 76(8):380. PubMed ID: 670799
[No Abstract] [Full Text] [Related]
30. Survival from brain tumours in England and Wales up to 2001.
Rachet B; Mitry E; Quinn MJ; Cooper N; Coleman MP
Br J Cancer; 2008 Sep; 99 Suppl 1(Suppl 1):S98-101. PubMed ID: 18813276
[No Abstract] [Full Text] [Related]
31. Hypertabastic survival model.
Tabatabai MA; Bursac Z; Williams DK; Singh KP
Theor Biol Med Model; 2007 Oct; 4():40. PubMed ID: 17963492
[TBL] [Abstract][Full Text] [Related]
32. The Study Was Subject to Considerable Bias.
Haupt M
Dtsch Arztebl Int; 2018 Nov; 115(40):674. PubMed ID: 30381134
[No Abstract] [Full Text] [Related]
33. The role of cytoreductive surgery in multifocal/multicentric glioblastomas.
Dimov D; Brainman D; Berger B; Coras R; Grote A; Simon M
J Neurooncol; 2023 Sep; 164(2):447-459. PubMed ID: 37697210
[TBL] [Abstract][Full Text] [Related]
34. Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?
Skaga E; Skretteberg MA; Johannesen TB; Brandal P; Vik-Mo EO; Helseth E; Langmoen IA
Neurooncol Adv; 2021; 3(1):vdab008. PubMed ID: 33665615
[TBL] [Abstract][Full Text] [Related]
35. Comparison of survival outcomes among cancer patients treated in and out of clinical trials.
Unger JM; Barlow WE; Martin DP; Ramsey SD; Leblanc M; Etzioni R; Hershman DL
J Natl Cancer Inst; 2014 Mar; 106(3):dju002. PubMed ID: 24627276
[TBL] [Abstract][Full Text] [Related]
36. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison.
Piroth MD; Pinkawa M; Holy R; Stoffels G; Demirel C; Attieh C; Kaiser HJ; Langen KJ; Eble MJ
Radiat Oncol; 2009 Nov; 4():57. PubMed ID: 19930657
[TBL] [Abstract][Full Text] [Related]
37. Modeling Adult Gliomas Using RCAS/t-va Technology.
Hambardzumyan D; Amankulor NM; Helmy KY; Becher OJ; Holland EC
Transl Oncol; 2009 May; 2(2):89-95. PubMed ID: 19412424
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate.
Vist GE; Bryant D; Somerville L; Birminghem T; Oxman AD
Cochrane Database Syst Rev; 2008 Jul; 2008(3):MR000009. PubMed ID: 18677782
[TBL] [Abstract][Full Text] [Related]
39. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme.
Kraus JA; Wenghoefer M; Glesmann N; Mohr S; Beck M; Schmidt MC; Schröder R; Berweiler U; Roggendorf W; Diete S; Dietzmann K; Heuser K; Müller B; Fimmers R; von Deimling A; Schlegel U
J Neurooncol; 2001 May; 52(3):263-72. PubMed ID: 11519857
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic astrocytoma in immune competent dogs.
Berens ME; Giese A; Shapiro JR; Coons SW
Neoplasia; 1999 Jun; 1(2):107-12. PubMed ID: 10933043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
